Amphastar Pharmaceuticals Inc
AMPH27.120USD
+0.310+1.16%
Handelsschluss 12/26, 16:00（ET）Kurse um 15 Minuten verzögert
1.26BMarktkapitalisierung
11.50KGV TTM
mehr Informationen über Amphastar Pharmaceuticals Inc Unternehmen
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Amphastar Pharmaceuticals Inc Informationen
BörsenkürzelAMPH
Name des UnternehmensAmphastar Pharmaceuticals Inc
IPO-datumJun 25, 2014
CEOZhang (Yongfeng Yongfeng)
Anzahl der mitarbeiter2028
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse11570 6th St
StadtRANCHO CUCAMONGA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl91730
Telefon19099809484
Websitehttps://amphastar.com/
BörsenkürzelAMPH
IPO-datumJun 25, 2014
CEOZhang (Yongfeng Yongfeng)
Führungskräfte von Amphastar Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Mr. Jacob Liawatidewi
Mr. Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
--
--
Mr. Dan Dischner
Mr. Dan Dischner
Vice President - Corporate Communications
Vice President - Corporate Communications
--
--
Ms. Diane G. Gerst
Ms. Diane G. Gerst
Independent Director
Independent Director
--
--
Mr. David Gaugh
Mr. David Gaugh
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
167.00M
95.75%
France
7.11M
4.08%
China
299.00K
0.17%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
Andere
58.80%
Aktionäre
Aktionäre
Anteil
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
Andere
58.80%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
40.55%
Investment Advisor/Hedge Fund
22.63%
Corporation
14.86%
Individual Investor
9.43%
Hedge Fund
6.47%
Research Firm
2.82%
Pension Fund
1.06%
Bank and Trust
0.34%
Sovereign Wealth Fund
0.12%
Andere
1.72%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
586
33.97M
85.20%
+16.67K
2025Q3
603
33.96M
84.80%
+202.84K
2025Q2
607
33.74M
83.87%
-544.61K
2025Q1
597
34.53M
80.40%
-3.80M
2024Q4
593
35.69M
79.40%
-112.11K
2024Q3
575
35.68M
75.48%
+965.70K
2024Q2
565
34.64M
73.86%
+833.26K
2024Q1
548
33.97M
73.49%
-1.92M
2023Q4
531
33.91M
72.12%
+1.03M
2023Q3
499
32.97M
71.03%
+509.94K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Applied Physics & Chemistry Laboratories, Inc.
6.83M
14.68%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.12M
11.02%
-399.35K
-7.23%
Jun 30, 2025
Zhang (Jack Yongfeng)
2.62M
5.64%
+200.00K
+8.25%
Jun 13, 2025
The Vanguard Group, Inc.
2.67M
5.73%
+251.01K
+10.40%
Jun 30, 2025
TD Asset Management Inc.
2.03M
4.38%
-177.21K
-8.01%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.63M
3.5%
+270.52K
+19.94%
Jun 30, 2025
State Street Investment Management (US)
1.58M
3.39%
-28.38K
-1.77%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
1.26M
2.72%
+174.00
+0.01%
Jun 30, 2025
Boston Trust Walden Company
1.18M
2.53%
-39.17K
-3.22%
Jun 30, 2025
Epoch Investment Partners, Inc.
1.24M
2.67%
-19.94K
-1.58%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco Pharmaceuticals ETF
2.25%
State Street SPDR S&P Pharmaceuticals ETF
1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Invesco S&P SmallCap 600 GARP ETF
1.12%
Acquirers Small and Micro Deep Value ETF
0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.77%
Invesco S&P SmallCap Health Care ETF
0.56%
First Trust Small Cap Value AlphaDEX Fund
0.5%
Distillate Small/Mid Cash Flow ETF
0.45%
VictoryShares Small Cap Free Cash Flow ETF
0.37%
Mehr Anzeigen
Invesco Pharmaceuticals ETF
Anteil2.25%
State Street SPDR S&P Pharmaceuticals ETF
Anteil1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.38%
Invesco S&P SmallCap 600 GARP ETF
Anteil1.12%
Acquirers Small and Micro Deep Value ETF
Anteil0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil0.77%
Invesco S&P SmallCap Health Care ETF
Anteil0.56%
First Trust Small Cap Value AlphaDEX Fund
Anteil0.5%
Distillate Small/Mid Cash Flow ETF
Anteil0.45%
VictoryShares Small Cap Free Cash Flow ETF
Anteil0.37%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Amphastar Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Amphastar Pharmaceuticals Inc sind:
Applied Physics & Chemistry Laboratories, Inc. hält 6.83M Aktien, was 14.68% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 5.12M Aktien, was 11.02% der Gesamtaktien entspricht.
Zhang (Jack Yongfeng) hält 2.62M Aktien, was 5.64% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 2.67M Aktien, was 5.73% der Gesamtaktien entspricht.
TD Asset Management Inc. hält 2.03M Aktien, was 4.38% der Gesamtaktien entspricht.
Applied Physics & Chemistry Laboratories, Inc. hält 6.83M Aktien, was 14.68% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 5.12M Aktien, was 11.02% der Gesamtaktien entspricht.
Zhang (Jack Yongfeng) hält 2.62M Aktien, was 5.64% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 2.67M Aktien, was 5.73% der Gesamtaktien entspricht.
TD Asset Management Inc. hält 2.03M Aktien, was 4.38% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Amphastar Pharmaceuticals Inc?
Die drei wichtigsten Anteilseigner-Typen von Amphastar Pharmaceuticals Inc sind:
Applied Physics & Chemistry Laboratories, Inc.
BlackRock Institutional Trust Company, N.A.
Zhang (Jack Yongfeng)
Applied Physics & Chemistry Laboratories, Inc.
BlackRock Institutional Trust Company, N.A.
Zhang (Jack Yongfeng)
Wie viele Institutionen halten Anteile an Amphastar Pharmaceuticals Inc (AMPH)?
Mit Stand vom 2025Q4 halten 586 Institutionen Anteile an Amphastar Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 33.97M, was 85.20% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um 0.40% gestiegen.
Was ist die größte Einnahmequelle von Amphastar Pharmaceuticals Inc?
Am FY2025Q2 erzielte das Geschäft mit -- für Amphastar Pharmaceuticals Inc den höchsten Umsatz in Höhe von --, was --% des Gesamtumsatzes entspricht.
